Myocardial ischemia during intravenous DSA in patients with cardiac disease.
A prospective study was performed for 48 patients who had histories of angina and were referred for digital subtraction angiography (DSA). Cardiac disease was graded according to the American Heart Association (AHA) functional classification system. Each patient received 2-5 injections of 40-ml diatrizoate meglumine and diatrizoate sodium (Renografin-76, Angiovist-370, or MD-76) at 15 ml per second in the superior vena cava. Of the 28 patients in functional Classes I or II (no or slight limitation of activity), 11% had angina and 32% had definite ischemic ECG changes after the DSA injections. Of the 19 patients in functional Class III (marked limitation of activity), 63% had angina, and 58% had definite ischemic ECG changes after the injections. One patient in functional Class IV (total disability) developed ventricular fibrillation after the second injection. These observed cardiac effects following bolus injections of hypertonic ionic contrast media indicate that special precautions are necessary when performing intravenous DSA examinations on this group of high risk patients.
D000368:Aged; D000787:Angina Pectoris / Q000209:etiology*; D000792:Angiography / Q000009:adverse effects*; D001145:Arrhythmias, Cardiac / Q000209:etiology; D002118:Calcium / Q000009:adverse effects; D002614:Chelating Agents / Q000009:adverse effects; D003287:Contrast Media / Q000009:adverse effects; D003327:Coronary Disease / Q000209:etiology*; D004562:Electrocardiography; D005260:Female; D006331:Heart Diseases / Q000145:classification / Q000000981:diagnostic imaging*; D006439:Hemodynamics; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013382:Subtraction Technique
D002614:Chelating Agents; D003287:Contrast Media; D002118:Calcium